Pharma major Zydus Cadila on July 1 applied for Emergency Use Authorisation (EUA) seeking approval from the Drugs Controller General of India (DCGI) for the launch of their ZyCoV-D vaccine for 12 years and above, sources said on Thursday. The company plans to manufacture up to 120 million doses of the shot annually.

Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children". It said.

Zydus claims its vaccine is 66.6 percent effective against symptomatic Covid cases and 100 percent for moderate disease. It also says the vaccine is safe for children between 12 and 18 years. But its trial data is not peer-reviewed yet. ZyCoV-D showed safety and efficacy in a late-stage trial with more than 28,000 volunteers across the country, including about 1,000 subjects in the 12-18 year age group, Zydus says.

UP CM Yogi Adityanath to roll out relief for Covid widows

Why Team India lost in the WTC final, Sunil Gavaskar reveals real reason

94 new corona patients found in Delhi, 6 killed in last 24 hours